SIAE Rare Variants in Juvenile Idiopathic Arthritis and Primary Antibody Deficiencies

Eirini Sevdali,1 Elena Tsitsami,2 Maria Tsinti,2 Evangelia Farmaki,3 Efimia Papadopoulou-Alataki,4 Anastasios E. Germenis,1 and Matthaios Speletas1

1Department of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 415 00 Larissa, Greece
2Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children’s Hospital “Aghia Sophia”, University of Athens, 115 27 Athens, Greece
3First Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece
4Fourth Department of Pediatrics, General Regional Hospital Papageorgiou, Aristotle University of Thessaloniki, 564 03 Thessaloniki, Greece

Correspondence should be addressed to Matthaios Speletas; maspel@med.uth.gr

Received 20 April 2017; Accepted 18 July 2017; Published 16 August 2017

Copyright © 2017 Eirini Sevdali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sialic acid acetyltransferase (SIAE) deficiency was suggested to lower the levels of ligands for sialic acid-binding immunoglobulin-like receptors, decreasing the threshold for B-cell activation. In humans, studies of rare heterozygous loss-of-function mutations in SIAE gene in common autoimmune diseases, including juvenile idiopathic arthritis (JIA), yielded inconsistent results. Considering the distinct pathogenesis of the two main subtypes of JIA, autoinflammatory systemic (sJIA) and autoimmune oligo/polyarticular (aJIA), and a predisposition to autoimmunity displayed by patients and families with primary antibody deficiencies (PADs), the aim of our study was to analyze whether SIAE rare variants are associated with both the phenotype of JIA and the autoimmunity risk in families with PADs. A cohort of 69 patients with JIA, 117 healthy children, 54 patients, and family members with PADs were enrolled in the study. Three novel SIAE variants (p.Q343P, p.Y495X, and c.1320+33T>C) were found only in patients with aJIA but interestingly also in their healthy relatives without autoimmunity, while none of PAD patients or their relatives carried SIAE defects. Our results show that SIAE rare variants are not causative of autoimmunity as single defects.

1. Introduction

Autoimmune diseases represent a heterogeneous group of disorders characterized by hyperactive immune responses against “self,” potentially, due to the inability of the immune system to recognize self-antigens from pathogens. The majority of these diseases are non-Mendelian polygenic diseases, in which underlying complex genetic and gene regulatory mechanisms, in combination with environmental stimuli, lead to the emergence of autoimmunity [1, 2]. Genome-wide association studies have revealed a wide spectrum of common variants at hundreds of loci that contribute to autoimmune disease susceptibility; many of them are located into genes that are master regulators of immunological function ([11], reviewed in [3]). However, the effect size of these DNA polymorphisms is modest, as they account for relatively little disease risk and heritability; therefore, their contribution to developing autoimmunity is relatively low. It has been suggested that rare alleles of a large effect could account for what is called as “missing heritability,” out of the context of “common disease-common allele” hypothesis [4]. Nevertheless, Hunt et al. have shown recently that rare coding region variants have minor contribution in common autoimmune disease susceptibility, suggesting that multiple common variant signals of a weak effect could account for the missing heritability, instead of the rare ones [5].
Sialic acid acetylerase (SIAE, Ensembl: ENSG00000110013) is an enzyme that regulates the cell surface acetylation of sialic acids. It has been proposed that SIAE functions in a B-cell intrinsic manner to prevent overactivation of B-cells by setting a threshold for B-cell receptor (BCR) signaling, contributing to the maintenance of immunological tolerance in mice [6, 7]. However, Mahajan et al. have recently revealed that the striking immunophenotype of SIAE-deficient mice that was described by Cariappa et al. [6] was attributed to a homozygous copy number variant in Dock2 gene in a commercially available C57BL/6 mouse strain that has been used for backcrossing and that SIAE-deficient mice display no defects in B-cell development [8].

Nevertheless, rare heterozygous SIAE defects were first described by Surolia et al. as being enriched in patients with common autoimmune diseases; the majority of them constitute changes in highly evolutionary conserved sites, affecting protein catalytic function and in vitro secretion [9]. Analysis of the genetic locus of SIAE in 66,924 individuals of European ancestry failed to replicate the findings of Surolia et al. [9, 10]. Accordingly, several subsequent studies have reported varying results regarding the significance of SIAE locus in autoimmune disease susceptibility [11–16]. In this context, it has been suggested that further studies, including family-based association, should be applied in order to elucidate the precise role of rare SIAE variants in autoimmune pathogenesis [9, 10].

Among the diseases analyzed in initial studies was juvenile idiopathic arthritis (JIA), the most common rheumatic disorder of childhood [9, 10], but no data regarding disease subtypes were provided. This is an important point, considering that JIA is characterized by clinically distinct manifestations, such as autoimmune oligoarticular JIA (oJIA) and polyarticular JIA (pJIA), which are the most commonly encountered forms (primarily oJIA), and the less common autoinflammatory systemic JIA (sJIA) [17]. Distinct genetic mechanisms are yielded behind the emergence of the different JIA phenotypes; oJIA and pJIA represent antigen-driven autoimmune diseases, as indicated by their positive associations with HLA genes, in contrast to the uncontrolled activation of the innate immune system, leading to the multisystem inflammation that characterizes sJIA (reviewed in [18]). Earlier genetic studies tended to group all children with JIA, while recent ones focus on the differences in JIA subtypes despite the inevitable reductions in sample size and subsequently the power of the study. However, the heterogeneity of the disease complicates the interpretation of the genetic data.

Moreover, autoimmune manifestations, including arthritis, represent one of the most severe complications in a proportion of patients with primary antibody deficiencies (PADs), which are associated with disturbed T- and B-cell homeostasis (reviewed in [19, 20]); however, it is still obscure whether autoimmunity and antibody deficiency share common genetic mechanisms. It has been reported that the presence of certain variants of immune genes, such as TACI, CTLA4, and LRBA, may be associated with the development of certain features of CVID [21]. It is also noteworthy that immunocompetent relatives of patients with PAD have an increased risk of developing autoimmunity ([22], reviewed in [23]).

Taking into consideration both the controversial association of rare SIAE variants with the emergence of JIA [9, 10] and the fact that SIAE locus has yet to be analyzed as a modifying genetic factor in PADs, the purpose of our study was to investigate the role of SIAE in the pathogenesis of these two multifactorial disorders. Moreover, due to the prevalence of autoimmunity in the family of patients with JIA and PADs, we analyzed the mutational status of SIAE in JIA and PADs relatives.

### 2. Materials and Methods

#### 2.1. Subjects

Two cohorts of patients were enrolled in the study. The first consists of 69 patients with JIA (male/female: 22/47, mean age: 9.8 years, and range: 2.5–18.3) attending at the First Department of Pediatrics of Children’s Hospital “Aghia Sophia,” University of Athens, Greece. Among them, 47 were diagnosed with oJIA (male/female: 11/36, mean age: 9.6 years, and range: 2.5–15.2), 11 with rheumatoid factor (RF-) negative pJIA (male/female: 4/7, mean age: 10.7 years, and range: 2.9–18.3), and 11 with sJIA (male/female: 7/4, mean age: 9.9 years, and range: 5.1–15.4), according to the International League Against Rheumatism criteria [24]. One hundred and seventeen (117) children without autoimmunity (male/female: 36/81, mean age: 9.7 years, and range: 2.4–18.0), presenting to outpatient clinic for common disorders (flu, diarrhea, and so forth), have served as an age- and sex-matched control group and were analyzed for the incidence of the three novel SIAE mutations identified in patients with aJIA. Moreover, 10 relatives of patients with aJIA displaying rare SIAE variants, with/without autoimmunity (male/female: 6/4, mean age: 29.1 years, and range: 3–53), were also analyzed.

The second cohort of patients consists of 45 individuals with PADs (male/female: 24/21, mean age at diagnosis: 23.0 years, and range: 4–79); among them, 12 patients suffered from common variable immunodeficiency (CVID) (male/female: 7/5, mean age: 32.0 years, and range: 4–70) and 33 from IgA deficiency (IgAD) (5 of them with a coexistent IgG4D; male/female: 17/16, mean: 19.7 years, and range: 4–79). The diagnosis of PADs was based on the recent revised ESID criteria (http://esid.org/Working-Parties/Registry/Diagnosis-criteria), and the majority of patients suffered from autoimmune diseases. Nine (9) family members (male/female: 3/6, mean age: 50.0 years, and range: 17–85) of 4 CVID patients, with/without autoimmunity, were also analyzed for SIAE variants. The clinical and demographic data of all individuals enrolled in the study are presented in detail in Table 1.

The study has received ethical approval by the Institutional Review Board of the University Hospital of Larissa and the Children’s Hospital “Aghia Sophia” of Athens, Greece. A written informed consent, prior to blood collection, was signed by all the participants as well as parents or relatives of patients where consent was not legally applicable (e.g., children). All experimental procedures performed were in accordance with the ethical standards.
|                           | Total | JIA   | sJIA | Controls | Total | PADs  | IgAD | PAD family members |
|---------------------------|-------|-------|------|----------|-------|-------|------|-------------------|
| Number                    | 69    | 58    | 11   | 117      | 45    | 12    | 33   | 9                 |
| Male/female               | 22/47 | 15/43 | 7/4  | 36/81    | 24/21 | 7/5   | 17/16| 3/6               |
| Age (years) (mean, range) | 9.8   | 9.8   | 9.9  | 9.7      | 9.7   | 23    | 19.7 | 50.0              |
| Arthritis (n, %)          | 69, 100 | 58, 100 | 11, 100 | 0, 0     | 7, 15.6 | 3, 25.0 | 4, 12.1 | 1, 11.1          |
| Autoimmune manifestations (n, %) | 58, 84.1 | 58, 100 | 0, 0 | 0, 0     | 28, 62.2 | 11, 91.7 | 17, 51.5 | 4, 44.4          |
| ITP (n, %)                | 6, 13.3 | 3, 25.0 | 3, 9.1 | 0, 0     |
| AHA (n, %)                | 2, 4.4 | 1, 8.3 | 1, 3.0 | 0, 0     |
| Pernicious anemia (n, %)  | 2, 4.4 | 2, 16.7 | 0, 0 | 0, 0     |
| Thyroid disease (n, %)    | 13, 28.9 | 6, 50.0 | 7, 21.2 | 1, 11.1 |
| Vitiligo (n, %)           | 2, 4.4 | 1, 8.3 | 1, 3.0 | 0, 0     |
| Diabetes mellitus (n, %)  | 7, 15.6 | 0, 0 | 7, 21.2 | 0, 0     |
| Celiac disease (n, %)     | 3, 6.7 | 0, 0 | 3, 9.1 | 0, 0     |
| Others (n, %)             | 3, 6.7 | 0, 0 | 3, 9.1 | 2, 22.2 |

AHA: autoimmune hemolytic anemia; aJIA: autoimmune juvenile idiopathic arthritis; CVID: common variable immunodeficiency; JIA: juvenile idiopathic arthritis; IgAD: IgA deficiency; ITP, idiopathic thrombocytopenic purpura; PADs, primary antibody deficiencies; sJIA, systemic juvenile idiopathic arthritis. *Arthritis is reported in each group regardless of the autoimmune background. †Including patients with lupus, catastrophic antiphospholipid syndrome, Raynaud’s syndrome, and autoimmune neutropenia.
of Helsinki declaration and its later amendments or comparable ethical standards.

2.2. Molecular Analyses. Peripheral blood samples were collected in K3-EDTA tubes from subjects during routine clinical visits; genomic DNA was isolated from samples using the QIAamp DNA Blood Mini Kit (Qiagen, Crawley, United Kingdom), according to manufacturers’ instructions, and SIAE variants were detected by direct sequencing after polymerase chain reaction (PCR) amplification of all 10 exons and the exon-intron boundaries, as it has previously been described [9].

Furthermore, according to our findings, we studied the incidence of three novel SIAE variants detected in patients with the autoimmune types of JIA (p.Q343P, p.Y495X, and c.1320+33T>C), in their relatives and the healthy control group. Thus, for the detection of c.1320+33T>C and p.Q343P alterations, we set up PCR restriction fragment length polymorphism assay (RFLP) protocols. In particular, for the detection of p.Q343P mutation, a 360 bp fragment (encompassing exon 8) was amplified by PCR and subjected to BtsCI overnight digestion (New England Biolabs, Ipswich, UK) at 50°C. The presence of undigested PCR products was indicative of wild-type samples, whereas the presence of the mutation resulted in the digestion of the PCR products to 210 bp and 150 bp fragments.

For the detection of c.1320+33T>C genetic variant, a 433 bp fragment (encompassing exon 9) was amplified by PCR and subjected to digestion with TspDTI (EURx, Gdańsk, Poland) at 70°C for 9 hours. Due to the presence of two TspDTI restriction sites, the wild-type PCR products were digested into 319, 89, and 25 bp fragments, while the presence of the mutated allele resulted in the loss of one restriction site and the identification of 2 fragments at 408 and 25 bp (homozygote) or 408, 319, 89, and 25 bp products (heterozygote). For the confirmation of the PCR-RFLP analysis results, the majority of PCR products of exons 9 and 30 randomly chosen PCR products of exon 8 were purified using a PCR purification system (Qiagen) and were directly sequenced using an ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA) and a BigDye Terminator DNA sequencing kit (Applied Biosystems).

Finally, the detection of p.Y495X mutation was performed by direct sequencing after PCR amplification of exon 10 (as mentioned above), since the presence of the mutated or the wild-type allele does not create any restriction enzyme site.

2.3. Bioinformatic Analyses. In order to determine if the novel SIAE rare variants could affect the structure and function of the protein, 4 bioinformatic packages have been used, namely, SIFT (Sorting Intolerant From Tolerant, available at http://sift.jcvi.org/), Provean (Protein Variation Effect Analyzer, available at http://provean.jcvi.org/index.php), PolyPhen-2 (Polymorphism Phenotyping v2, available at http://genetics.bwh.harvard.edu/pph2/), and Mutation taster (available at http://www.mutationtaster.org/).

2.4. Statistical Analysis. Fisher’s exact test (two-sided p values) has been used for the association analysis of the genotype frequency of novel SIAE variants between patients and controls. The above analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 22 (IBM Corporation, NY).

3. Results and Discussion

Three novel genetic SIAE variants were identified in the patients of the study, all in heterozygous state and only in patients with aJIA (Figure 1). The first alteration (c.1028A>C) was found in a patient with persistent antinuclear antibody- (ANA-) positive oJIA, resulting in the substitution of a neutral polar amino acid (glutamine) at the amino acid position 343 into a nonpolar amino acid (proline) (p.Q343P), within the catalytic portion of SIAE [25]. The second variant (c.1485C>A, p.Y495X) was a nonsense mutation in the C-terminal domain of SIAE, identified in a patient with RF-negative and ANA-positive pJIA. Finally, a novel genetic alteration located within intron 9 (c.1320+33T>C) of SIAE was found in a patient with persistent ANA-positive oJIA. Of note, these alterations were absent in patients with the autoinflammatory JIA subtype and in our healthy control group (odds ratio: 6.70, 95% confidence interval: 0.27–167.08, p = 0.312), as well as in all patients with PADs and their family members. Additionally, the examination of two public databases containing a detailed catalogue of variants derived from large-scale sequencing projects, the Exome Aggregation Consortium (available at http://exac.broadinstitute.org/) and the Exome Variant Server of the NHLBI GO Exome Sequencing Project (ESP) (available at http://evs.gs.washington.edu/EVS/), has shown that none of the novel mutations reported in this study have previously been identified.

The comparison of the nucleotide sequence of SIAE with nonredundant sequences present in NCBI using both the BLAST algorithm (available at https://blast.ncbi.nlm.nih.gov/Blast.cgi) and analysis with Mutation taster showed that the genetic alterations p.Q343P and p.Y495X involve residues that are conserved in serine hydrolases superfamily, in which SIAE belongs to, and are in consistence with the pattern of loss-of-function SIAE variants that have previously been described [9]. On the other hand, the intronic c.1320+33T>C alteration might also be damaging by affecting splicing, as supported by previous studies reporting the pathogenic significance of similar intronic defects (reviewed in [26]).

Bioinformatic tools can provide the predicted functional impact of coding variants supporting the interpretation of a possible consequence of a variant. In order to further elucidate the effect of the aforementioned alterations in protein function, we performed bioinformatic analysis, using 4 different tools, as mentioned above (Table 2). This type of analysis represents an alternative approach to identify whether a particular nucleotide and/or amino acid change results in profound structural alterations and, therefore, might influence functionally relevant parts of a protein. In this context, we identified that p.Q343P mutation involves a highly
conserved residue and might result in splice site changes by strengthening existing splice sites (according to the Mutation Taster tool); such an event might result in the loss of N-glycosylation sites at 401 and 422 residues and subsequently affect the catalytic activity of the enzyme, as glycosylation has been suggested a prerequisite to give rise to the biologically active form of the enzyme [25]. Considering the nonsense mutation p.Y495X, it is located in a partly conserved domain, despite the high degree of conservation of the 495 residue and results in a slightly truncated protein, with less than 10% of the full wild-type protein length being missing. The abovementioned mutation does not meet the criteria for a nonsense-mediated mRNA decay, as it does not follow the "55 boundary rule" [27, 28], since it is located within the last exon of SIAE, supporting its probable pathogenic role. Finally, considering the intronic alteration c.1320+33T>C, bioinformatic analyses indicated that it is probably not pathogenic (Table 2). Nevertheless, the results of bioinformatic analyses are indicative and further functional studies are necessary to provide conclusive remarks.

Furthermore, taking into consideration the high incidence of autoimmune diseases, mainly Hashimoto thyroiditis and rheumatoid arthritis, among first- and second-degree relatives of JIA patients [29], we investigated the prevalence of the novel variants in each respective patient’s family (Figure 2). Interestingly, in the first family, the patient’s father, diagnosed with asthma, was heterozygous for the p.Q343P variant, while the mother, diagnosed with Hashimoto’s disease, along with all other healthy siblings analyzed, carried the wild-type alleles (Figure 2(a)). Similarly, the healthy proband’s father carried the p.Y495X variant, while her mother and brother carried the wild-type alleles (Figure 2(b)); all individuals in this family did not suffer from autoimmunity. Finally, the healthy father and brother of the proband carrying the c.1320+33T>C alteration were also heterozygotes for this intronic variant (Figure 2(c)). All the aforementioned family members carrying the novel rare SIAE alterations were negative for ANA.

As presented in detail in Table 3, a number of previously described common single-nucleotide polymorphisms (SNPs) have also been identified in patients and controls of the study. The majority of them were silent polymorphisms (p.S156=, p.R340=, and p.T484=), and the p.T484= and p.S156= polymorphisms in our population are related ($\chi^2 = 47.50$, $p < 0.001$), which is in accordance with findings from the European population (LDlink, http://analysistools.nci.nih.gov/LDlink). Moreover, the catalytically intact SIAE variants p.K71R, p.M89V, and p.A467V [14] were also identified in heterozygosity in both patients and controls (Table 3). It is noteworthy that the p.F404S mutation, a catalytically defective variant found both in a patient with JIA and in a relative with systemic lupus erythematosus but in none of 648 healthy subjects analyzed by Surolia et al. [9], was found in one individual of our healthy control group.

A strong genetic contribution may be more likely in JIA, as children have less time for environmental exposure that could influence disease risk. The strongest genetic contribution to the occurrence of aJIA has been attributed to the HLA locus, estimated to explain approximately 13% of the total variation in JIA susceptibility [30], confirming that

![Figure 1: The novel SIAE rare variants identified in the patients of the study: (a) p.Q343P, (b) p.Y495X, and (c) c.1320+33T>C.](image-url)
Table 2: Bioinformatic analysis of novel SIAE genetic variants in patients with autoimmune juvenile idiopathic arthritis.

| Number | Location | DNA numbering | cDNA numbering | Amino acid substitution | PolyPhen-2 (score, sensitivity, specificity) | SIFT (score) | PROVEAN (score) | Mutation taster (probability) | Genotypesa (allelic frequency)b |
|--------|----------|---------------|----------------|-------------------------|-----------------------------------------------|--------------|----------------|-------------------------------|-------------------------------|
| 1      | Exon 8   | g.41498A>C    | c.1028A>C      | Q343P                   | Probably damaging (1.000, 0.00, 1.00)         | Damaging (0.00) | Deleterious (−5.483) | Disease causing (0.999)      | oJIA 0/1/46 0.011  pJIA 0/0/11 0.000  sJIA 0/0/11 0.000  Controls 0/0/117 0.000 |
| 2      | Intron 9 | g.42795T>C    | c.1320+33T>C   | —                       | N/A                                           | N/A           | N/A             | Polymorphism (0.999)         | oJIA 0/1/46 0.011  pJIA 0/0/11 0.000  sJIA 0/0/11 0.000  Controls 0/0/117 0.000 |
| 3      | Exon 10  | g.44266C>A    | c.1485C>A      | Y495X                   | N/A                                           | N/A           | Deleterious (−7.200) | Disease causing (0.999)      | oJIA 0/0/47 0.045  pJIA 0/1/10 0.000  sJIA 0/0/11 0.000  Controls 0/0/117 0.000 |

aGenotype: homozygous/heterozygous/wild type. bAllele frequency of all SIAE rare defects (in total) in patients with autoimmune JIA: 0.009. The numbering of cDNA and amino acids corresponds to SIAE transcript: ENST00000263593.7.
there are still many non-HLA loci to be identified. Various SNPs in other genes of the immune system (i.e., TRAF1-C5, VTCN1, and PTPN22) have been revealed through genome-wide association studies (GWAS) as candidate JIA-predisposing loci (reviewed in [31]). However, common SNPs account for only one third of JIA susceptibility, rather higher than other complex autoimmune diseases, while the rest is attributed to rare variants, gene regulatory mechanisms, and gene-environment interactions (reviewed in [31, 32]). In this context, SIAE mutations may represent such rare defects that in concert with additional defects and/or interactions may contribute to the emergence of autoimmunity.

In regard with the analysis of SIAE in patients with PADs and their relatives, none of them was found to carry rare SIAE variants. Nevertheless, a number of known functionally intact SIAE variants (missense: p.G64S, p.K71R, and p.M89V and silent: p.L143=, p.S156=, and p.T484=) were identified in patients with PADs and their relatives with/without autoimmunity, without significant differences among disease subgroups (Table 4).

To the best of our knowledge, this is the first study investigating a possible contribution of the SIAE gene in the occurrence of autoimmunity in PADs. Autoimmunity represents one of the prevalent and most severe complications in CVID and IgAD, while a clustering of various autoimmune diseases has also been reported in the family environment of the affected patients [22, 23]. However, the genetic mechanisms behind the emergence of autoimmunity in these polygenic diseases are still not fully understood [19]. Taking into consideration the rare nature and heterogeneity of these disorders, we could not exclude a possible contribution of SIAE defects to the pathogenesis of autoimmunity in some patients with PADs. Therefore, the analysis of larger cohorts of such patients might be more determinant in confirming or not our results.

4. Conclusion

In this study, we identified novel SIAE mutations in patients with JIA; however, these rare variants were also present in patients’ relatives without autoimmunity, supporting the notion that SIAE rare variants might have variable penetrance in the emergence of autoimmunity. On the other hand, we did not find rare SIAE alterations either in patients with PADs or in their relatives with autoimmunity. Thus, we conclude that rare SIAE variants do not result in overt autoimmunity as single defects. However, we cannot exclude the possibility that such variants might have an additive effect with other autoimmune disease risk loci. At the end, it is also clear that in the case of high heritability complex disorders, as autoimmune diseases, a number of clinically well-defined patients, families, and controls are required in order to draw reliable conclusions.
| Number | Location | DNA numbering | cDNA numbering | Amino acid substitution | rs     | Total Allele frequency | Autoimmune JIA | pJIA | sJIA | Controls | Europeans (NCBI) | Allele frequency |
|--------|----------|---------------|----------------|------------------------|--------|------------------------|----------------|------|------|----------|----------------|-----------------|
| 1      | 5′ UTR   | g.7560T>G     | c.-36T>G        |                        | rs55947628 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | N/A          |
| 2      | 5′ UTR   | g.7585T>A     | c.-11T>A        |                        | rs20201641 | 0.000 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | N/A | N/A | 0.002 |
| 3      | Exon 2   | g.11927A>G    | c.212A>G        | K71R                  | rs12282107 | 0.000 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | N/A | N/A | 0.007 |
| 4      | Intron 2 | g.11964G>A    | c.229+20G>A     |                       | rs512225 | 0.233 | 3/18/26 | 0.255 | 0/3/8 | 0.136 | 0/5/6 | 0.227 | N/A | N/A | 0.251 |
| 5      | Exon 3   | g.20536A>G    | c.265A>G        | M89V                  | rs78778622 | 0.026 | 0/3/44 | 0.032 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | N/A | N/A | 0.051 |
| 6      | Exon 4   | g.26573T>C    | c.468T>C        | S156S                 | rs1942663 | 0.017 | 0/1/46 | 0.011 | 0/1/10 | 0.045 | 0/1/10 | 0.045 | N/A | N/A | 0.024 |
| 7      | Intron 5 | g.31722C>T    | c.722+37C>T     |                       | rs7930393 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | N/A | N/A | 0.023 |
| 8      | Intron 5 | g.31750C>T    | c.722+65C>T     |                       | rs49793694 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | N/A | N/A | N/A  |
| 9      | Intron 7 | g.33978C>T    | c.966+39C>T     |                       | rs14273712 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | N/A | N/A | 0.005 |
| 10     | Exon 8   | g.41490T>C    | c.1020T>C       | R340R                 | rs35451312 | 0.009 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | N/A | N/A | 0.007 |
| 11     | Intron 8 | g.41675A>G    | c.1124+81A>G    |                       | rs620499 | 0.069 | 0/8/39 | 0.085 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | N/A | N/A | N/A  |
| 12     | Intron 8 | g.42499C>T    | c.1125-68C>T    |                       | rs77343428 | 0.017 | 0/1/46 | 0.011 | 0/1/10 | 0.045 | 0/1/10 | 0.045 | 0/4/103 | 0.023 | N/A  |
| 13     | Intron 8 | g.42501T>C    | c.1125-66T>C    |                       | rs14028821 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | 0/2/105 | 0.009 | N/A  |
| 14     | Exon 9   | g.42653T>C    | c.1211T>C       | F404S                 | rs201877149 | 0.000 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | 0/1/106 | 0.005 | 0.002 |
| 15     | Intron 9 | g.44078C>T    | c.1321-24C>T    |                       | rs38194723 | 0.078 | 0/8/39 | 0.085 | 0/1/10 | 0.045 | 0/1/10 | 0.045 | 0/10/107 | 0.043 | 0.029 |
| 16     | Exon 10  | g.44181C>T    | c.1400C>T       | A467V                 | rs7941523 | 0.000 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | 0/1/16 | 0.004 | 0.003 |
| 17     | Exon 10  | g.44233G>A    | c.1452G>A       | T484T                 | rs7941327 | 0.009 | 0/1/46 | 0.011 | 0/0/11 | 0.000 | 0/1/10 | 0.045 | 0/3/114 | 0.013 | 0.024 |
| 18     | 3′ UTR   | g.44414G>C    | c.61G>C         |                       | rs45715586 | 0.000 | 0/0/47 | 0.000 | 0/0/11 | 0.000 | 0/0/11 | 0.000 | 0/1/16 | 0.004 | N/A  |

aGenotype: homozygous/heterozygous/wild type. The numbering of cDNA and amino acids corresponds to SIAE transcript: ENST00000263593.7.
| Number | Location | DNA numbering | cDNA numbering | Amino acid substitution | rs    | Genotypesa | Allele frequency | Genotypesa | Allele frequency | Genotypesa | Allele frequency | Genotypesa | Allele frequency | Genotypesa | Allele frequency |
|--------|----------|---------------|---------------|-------------------------|-------|------------|------------------|------------|------------------|------------|------------------|------------|------------------|------------|------------------|
| 1      | Exon 2   | g.11905G>A    | c.190G>A      | G64S                   | rs76655561 | 0/0/12      | 0.000            | 0/1/32 | 0.015            | 0.000      | 0/0/9            | 0.000      | 0.000            | 0.003      | 0.000            |
| 2      | Exon 2   | g.11927A>G    | c.212A>G      | K71R                   | rs12282107 | 0/0/12      | 0.000            | 0/1/32 | 0.015            | 0.000      | 0/0/9            | 0.000      | 0.000            | 0.007      | 0.000            |
| 3      | Exon 2   | g.11964G>A    | c.229+20G>A   | rs512225               | 0/5/7   | 0.208      | 0.227            | 1/10/22 | 0.182            | 0.176      | 0/3/6            | 0.167      | 0.125            | 0.251      | 0.051            |
| 4      | Exon 3   | g.20536A>G    | c.265A>G      | M89V                   | rs78778622 | 0/1/11      | 0.042            | 0.045  | 0.030            | 0.029      | 0/1/8            | 0.056      | 0.125            | 0.051      | 0.000            |
| 5      | Exon 4   | g.26532T>C    | c.427T>C      | L143L                  | rs201552273 | 0/0/12      | 0.000            | 0.000  | 0.015            | 0.000      | 0/0/9            | 0.000      | 0.000            | 0.001      | 0.000            |
| 6      | Exon 4   | g.26573T>C    | c.468T>C      | S156S                  | rs1942663 | 0/0/12      | 0.000            | 0.000  | 0.030            | 0.029      | 0/0/9            | 0.000      | 0.000            | 0.024      | 0.000            |
| 7      | Intron 5 | g.31722C>T    | c.722+37C>T   | rs79300393             | 0/0/12   | 0.000      | 0.000            | 0/1/32 | 0.015            | 0.029      | 0/0/9            | 0.000      | 0.000            | 0.023      | 0.000            |
| 8      | Intron 7 | g.33978C>T    | c.966+39C>T   | rs142737112            | 0/0/12   | 0.000      | 0.000            | 0/1/32 | 0.015            | 0.029      | 0/0/9            | 0.000      | 0.000            | 0.005      | 0.000            |
| 9      | Intron 8 | g.41675A>G    | c.1124+81A>G  | rs620499               | 0/1/11   | 0.042      | 0.045            | 0/4/29 | 0.061            | 0.029      | 0/1/8            | 0.056      | 0.000            | N/A        | 0.000            |
| 10     | Intron 8 | g.42499C>T    | c.1125-68C>T  | rs77343428             | 0/0/12   | 0.000      | 0.000            | 0/1/32 | 0.015            | 0.000      | 0/0/9            | 0.000      | 0.000            | N/A        | 0.000            |
| 11     | Intron 9 | g.44078C>T    | c.1321-24C>T  | rs138194723            | 0/1/11   | 0.042      | 0.045            | 0/0/33 | 0.000            | 0.000      | 0/1/8            | 0.056      | 0.125            | 0.029      | 0.024            |
| 12     | Exon 10  | g.44233G>A    | c.1452G>A     | T484T                  | rs7941327 | 0/0/12      | 0.000            | 0.000  | 0.030            | 0.029      | 0/0/9            | 0.000      | 0.000            | 0.024      | 0.000            |

aGenotypes: homozygous/heterozygous/wild type. The numbering of cDNA and amino acids corresponds to SIAE transcript: ENST00000263593.7.
Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

This research has been cofinanced by the European Union (European Social Fund (ESF)) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales, investing in knowledge society through the European Social Fund.

References

[1] A. Goris and A. Liston, “The immunogenetic architecture of autoimmune disease,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 3, 2012.

[2] J. Cho and M. Feldman, “Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies,” Nature Medicine, vol. 21, no. 7, pp. 730–738, 2015.

[3] P. Gregersen and T. Behrens, “Genetics of autoimmune diseases—disorders of immune homeostasis,” Nature Reviews Genetics, vol. 7, no. 12, pp. 917–928, 2006.

[4] X. Hu and M. Daly, “What have we learned from six years of GWAS in autoimmune diseases, and what is next?,” Current Opinion in Immunology, vol. 24, no. 5, pp. 571–575, 2012.

[5] K. A. Hunt, V. Mistry, N. A. Bockett et al., “Negligible impact of rare autoimmune-locus coding-region variants on missing heritability,” Nature, vol. 498, no. 7453, pp. 232–235, 2013.

[6] A. Cariappa, H. Takematsu, H. Liu et al., “B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase,” The Journal of Experimental Medicine, vol. 206, no. 1, pp. 125–138, 2008.

[7] S. Pillai, A. Cariappa, and S. Pirnie, “Esterases and autoimmunity: the sialic acid acetyleresterase pathway and the regulation of peripheral B cell tolerance,” Trends in Immunology, vol. 30, no. 10, pp. 488–493, 2009.

[8] V. Mahajan, E. Demissie, H. Mattoo et al., “Striking immune phenotypes in diverse gene-targeted mice are driven by a copy number variant originating from a commercially available C57BL/6 strain,” Cell Reports, vol. 15, no. 9, pp. 1901–1909, 2016.

[9] I. Surolia, S. Pirnie, V. Chellappa et al., “Functionally defective germline variants of sialic acid acetyleresterase in autoimmunity,” Nature, vol. 466, no. 7303, pp. 243–247, 2010.

[10] K. Hunt, D. Smyth, T. Balschun et al., “Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry,” Nature Genetics, vol. 44, no. 1, pp. 3–5, 2011.

[11] E. Gan, K. MacArthur, A. Mitchell, and S. Pearce, “The role of functionally defective rare germline variants of sialic acid acetyleresterase in autoimmune Addison’s disease,” European Journal of Endocrinology, vol. 167, no. 6, pp. 825–828, 2012.

[12] G. Hirschfield, G. Xie, E. Lu et al., “Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes,” Genes and Immunity, vol. 13, no. 4, pp. 328–335, 2012.

[13] N. Al-Yami, L. Al-Jbali, K. M AlGhamdi, and F. S. Alkuraya, “No evidence for rare pathological SIAE coding variants in patients with vitiligoro,” International Journal of Dermatology, vol. 52, no. 8, pp. 1019–1021, 2012.

[14] V. Chellappa, K. Taylor, K. Pedrick et al., “M89V sialic acid acetyl esterase (SIAE) and all other non-synonymous common variants of this gene are catalytically normal,” PLoS One, vol. 8, no. 1, article e53453, 2013.

[15] M. Yamamoto, G. Iguchi, H. Bando et al., “A missense single-nucleotide polymorphism in the sialic acid acetyleresterase (SIAE) gene is associated with anti-PIT-1 antibody syndrome,” Endocrine Journal, vol. 61, no. 6, pp. 641–644, 2014.

[16] D. Zhang, F. He, H. Liu, F. Hao, and J. Zhu, “Lack of association between rare mutations of the SIAE gene and rheumatoid arthritis in a Han Chinese population,” Genetics and Molecular Research, vol. 14, no. 4, pp. 41462–41468, 2015.

[17] B. Prakken, S. Albani, and A. Martini, “Juvenile idiopathic arthritis,” The Lancet, vol. 377, no. 9783, pp. 2138–2149, 2011.

[18] Y. Lin, C. Wang, M. Gershwin, and B. Chiang, “The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis,” Autoimmunity Reviews, vol. 10, no. 8, pp. 482–489, 2011.

[19] A. Durandy, S. Kracker, and A. Fischer, “Primary antibody deficiencies,” Nature Reviews Immunology, vol. 13, no. 7, pp. 519–533, 2013.

[20] B. Grimbacher, K. Warnatz, P. F. Yong, A. S. Korganov, and H. H. Peter, “The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects,” Journal of Allergy and Clinical Immunology, vol. 137, no. 1, pp. 3–17, 2016.

[21] D. J. Bogaert, M. Dullaers, B. N. Lambrecht, K. Y. Vermaelen, E. BaereDe, and F. Haerynck, “Genes associated with common variable immunodeficiency: one diagnosis to rule them all?,” Journal of Medical Genetics, vol. 53, no. 9, pp. 575–590, 2016.

[22] P. Hermans, J. Diaz-Buxo, and J. Stobo, “Idiopathic late-onset immunoglobulin deficiency,” The American Journal of Medicine, vol. 61, no. 2, pp. 221–237, 1976.

[23] D. Brandt and M. Gershwin, “Common variable immune deficiency and autoimmunity,” Autoimmunity Reviews, vol. 5, no. 7, pp. 465–470, 2006.

[24] R. Petty, T. Southwood, P. Manners et al., “International league of associations of rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,” The Journal of Rheumatology, vol. 31, no. 2, pp. 390–392, 2004.

[25] F. Oricio, E. Damiati, E. Giacopuzzi et al., “Human sialic acid acetyl esterase: towards a better understanding of a puzzling enzyme,” Glycobiology, vol. 25, no. 9, pp. 992–1006, 2015.

[26] F. Pagani and F. Baralle, “Opinion: genomic variants in exons and introns: identifying the splicing spoilers,” Nature Reviews Genetics, vol. 5, no. 5, pp. 389–396, 2004.

[27] J. Wang, J. P. Gudikote, O. R. Olivas, and M. Wilkinson, “Boundary-independent polar nonsense-mediated decay,” Glycobiology, vol. 25, no. 9, pp. 992–1006, 2015.

[28] S. Brogna and J. Wen, “Nonsense-mediated mRNA decay (NMD) mechanisms,” Nature Structural and Molecular Biology, vol. 16, no. 2, pp. 107–113, 2009.

[29] S. Prahalad, E. Shear, S. Thompson, E. Giannini, and D. Glass, “Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 46, no. 7, pp. 1851–1856, 2002.
[30] K. Murray, M. Moroldo, P. Donnelly et al., "Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles," *Arthritis and Rheumatism*, vol. 42, no. 9, pp. 1843–1853, 1999.

[31] A. Hersh and S. Prahalad, "Immunogenetics of juvenile idiopathic arthritis: a comprehensive review," *Journal of Autoimmunity*, vol. 64, pp. 113–124, 2015.

[32] G. Gibson, "Rare and common variants: twenty arguments," *Nature Reviews Genetics*, vol. 13, no. 2, pp. 135–145, 2012.